Across TCGA pan-cancer cohorts, AVPR1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AVPR1B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher AVPR1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AVPR1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, PRAD, and UCEC are the cancer types where AVPR1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.164	0.635	.002	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.631	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: AVPR1B tumor-vs-normal RNA expression · all AVPR1B data types